Galectin Therapeutics CEO Peter G. Traber Buys 4,000 Shares (GALT)
Galectin Therapeutics (NASDAQ:GALT) CEO Peter G. Traber acquired 4,000 shares of the company’s stock in a transaction dated Thursday, August 14th. The shares were purchased at an average cost of $4.46 per share, with a total value of $17,840.00. Following the completion of the transaction, the chief executive officer now directly owns 101,333 shares of the company’s stock, valued at approximately $451,945. The purchase was disclosed in a filing with the SEC, which is available at this link.
GALT has been the subject of a number of recent research reports. Analysts at Aegis downgraded shares of Galectin Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 1st. Separately, analysts at BMO Capital Markets reiterated a “positive” rating on shares of Galectin Therapeutics in a research note on Tuesday, July 29th. Finally, analysts at MLV & Co
cut their price target on shares of Galectin Therapeutics from $27.00 to $15.00 in a research note on Tuesday, July 29th. They now have a “buy” rating on the stock.
Galectin Therapeutics (NASDAQ:GALT) traded up 1.52% during mid-day trading on Friday, hitting $4.68. The stock had a trading volume of 287,537 shares. Galectin Therapeutics has a one year low of $4.28 and a one year high of $19.11. The stock has a 50-day moving average of $10.47 and a 200-day moving average of $12.81. The company’s market cap is $103.2 million.
Galectin Therapeutics (NASDAQ:GALT) last announced its earnings results on Thursday, August 7th. The company reported ($0.17) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.21) by $0.04. On average, analysts predict that Galectin Therapeutics will post $-0.95 earnings per share for the current fiscal year.
Galectin Therapeutics Inc (NASDAQ:GALT) is a development-stage company engaged in drug development to create new therapies for cancer and fibrotic disease.
Receive News & Ratings for Galectin Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.